Belgian neonatal AI monitoring start-up Innocens raises 1.5 million euros

post-title

Innocens, a Belgian biotech spin-off from the University of Antwerp, has secured 1.5 million euros in funding to accelerate the commercial rollout of its AI-driven monitoring system for neonatal intensive care.

The investment comes from BAN Flanders, BeAngels, NXT2, the Limburg investment company LRM, interuniversity fund Qbic, and existing shareholders.

The company is developing an AI-based Clinical Decision Support System that provides 24/7 risk predictions to help clinicians detect early signs of infections or sepsis in newborns admitted to neonatal intensive care units.

Following an initial funding round in 2023, this new capital injection will enable Innocens to complete an additional clinical validation study, obtain CE regulatory certification and strengthen its internal capabilities. These steps are essential for accelerating the company’s commercial expansion across Europe.

Related articles

Top